Product image of Minjuvi (Tafasitamab) supplied by GNH India

Minjuvi

Active Ingredient:
Tafasitamab
Origin:
EU

Minjuvi (Tafasitamab)

Tafasitamab, the active ingredient in Minjuvi, is a monoclonal antibody presented as an intravenous formulation for intravenous use. It selectively binds the CD19 antigen on malignant B‑cells and is indicated for the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma, typically in combination with lenalidomide.

GNH India supplies Minjuvi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and specialty pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved documentation, cold‑chain logistics where required, and responsive technical support to ensure safe and reliable product delivery.

Manufacturer / TM Owner

Incyte Biosciences Distribution B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Minjuvi (taf... ) is used in the treatment of B‑cell malignancies, specifically diffuse large B‑cell lymphoma.

  • Relapsed diffuse large B‑cell lymphoma (DLBCL): improves overall response rates when combined with lenalidomide.
  • Refractory diffuse large B‑cell lymphoma (DLBCL): provides an additional therapeutic option for patients who have failed prior regimens.
  • Combination therapy with lenalidomide: enhances antibody‑dependent cellular cytotoxicity against CD19‑positive lymphoma cells.

How It Works

  • Tafasitamab is a humanized IgG1 monoclonal antibody that binds with high affinity to the CD19 antigen expressed on the surface of normal and malignant B‑cells. Binding triggers antibody‑dependent cellular cytotoxicity (ADCC) by recruiting natural killer cells and macrophages, and also induces direct apoptosis of the targeted B‑cells, thereby reducing tumor burden in diffuse large B‑cell lymphoma. The antibody’s Fc region is engineered to enhance interaction with Fcγ receptors, further amplifying immune‑mediated cell killing.

Side Effects

Tafasitamab may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Infusion‑related reactions (fever, chills, flushing).
  • Fatigue or weakness.
  • Nausea or vomiting.
  • Headache.
  • Diarrhea.
  • Decreased appetite.

Serious or Rare Side Effects

  • Severe infections (including opportunistic infections).
  • Hepatic toxicity (elevated transaminases, hepatitis).
  • Anaphylaxis or severe hypersensitivity reactions.
  • Tumor lysis syndrome.
  • Cytopenias (neutropenia, thrombocytopenia).

Precautions & Warnings

Before initiating therapy, clinicians should assess patient suitability and monitor for potential complications.

  • Infusion monitoring: observe for reactions during and after administration.
  • Hepatic function: evaluate liver enzymes prior to treatment and periodically thereafter.
  • Infection risk: screen for active infections and vaccinate appropriately before therapy.
  • Hypersensitivity: avoid in patients with known allergy to tafasitamab or its excipients.
  • Pregnancy and lactation: use only if benefits outweigh potential risks.

Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Tafasitamab may interact with other agents that affect immune function or increase infection risk.

Major Interactions (Avoid)

  • Concurrent use of other monoclonic antibodies (e.g., rituximab) due to additive immunosuppression.
  • Live vaccines during treatment (risk of vaccine‑derived infection).
  • Strong immunosuppressants (e.g., high‑dose steroids) that may diminish efficacy.

Moderate Interactions (Monitor Closely)

  • Lenalidomide: requires coordinated dosing and safety monitoring.
  • Anticoagulants: monitor for bleeding if thrombocytopenia develops.
  • Hepatotoxic drugs: watch liver function tests.
  • Vaccinations (non‑live): schedule before therapy when possible.

Frequently Asked Questions

Minjuvi contains the monoclonal antibody tafasitamab and is indicated for the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma, usually in combination with the immunomodulatory drug lenalidomide.

Tafasitamab binds to the CD19 protein on the surface of malignant B‑cells. This binding activates immune cells through antibody‑dependent cellular cytotoxicity and also triggers direct programmed cell death, helping to reduce the number of cancerous B‑cells.

The dosing regimen for Minjuvi is determined by the treating physician based on the patient’s clinical condition, body weight, and combination with lenalidomide. Specific dose and schedule information are provided in the prescribing information and should not be altered without medical guidance.

Safety data for tafasitamab in pregnancy and lactation are limited. The product should be used only if the potential benefit justifies any potential risk to the fetus or infant, and clinicians should discuss possible risks with the patient.

To request Minjuvi, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

The primary alternative class is anti‑CD20 antibodies such as rituximab. While rituximab targets CD20, tafasitamab targets CD19 and is often used when disease is refractory to CD20‑directed therapy. Clinical studies suggest that the tafasitamab‑lenalidomide combination can achieve meaningful response rates in patients who have progressed after standard regimens.

Minjuvi must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Prior to infusion, the product should be inspected for particulate matter and used within the time frame specified in the manufacturer’s instructions.

Minjuvi is given as an intravenous infusion, typically over a period of 30 minutes to several hours depending on the protocol. The infusion is performed in a clinical setting where vital signs can be monitored, and patients are observed for any immediate infusion‑related reactions.

Serious risks include severe infusion‑related reactions, opportunistic infections, hepatic toxicity, tumor lysis syndrome, and rare cases of anaphylaxis. Patients should be closely monitored for signs of infection, liver enzyme elevations, and any acute allergic response during and after the infusion.

Minjuvi is contraindicated in patients with known hypersensitivity to tafasitamab or any of its excipients. Caution is advised for individuals with severe hepatic impairment, active uncontrolled infections, or those who are pregnant or breastfeeding unless the potential benefit outweighs the risk.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Tafasitamab

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT